Morepen Laboratories has secured one of the largest Contract Development and Manufacturing Organisation (CDMO) mandates in its history, winning a multi-year global order valued at around ₹825 crore ($91 million) from a leading international pharmaceutical major.
The supplies under the agreement are expected to commence within the next four to five months, with execution scheduled through the first quarter of the following financial year, subject to customary operational and regulatory clearances.
Strategic Push In High-Growth CDMO Space
The deal marks a significant milestone in Morepen’s strategic push to deepen its presence in the fast-growing global CDMO segment, which is increasingly becoming central to pharmaceutical supply chains worldwide. By leveraging its four decades of active pharmaceutical ingredient (API) manufacturing experience, the company is positioning itself as a long-term development and manufacturing partner for global innovators.
The mandate underlines the growing customer confidence in Morepen’s regulatory track record and manufacturing reliability. The company operates internationally accredited facilities approved by the US Food and Drug Administration (USFDA), WHO-GMP, and European authorities, enabling it to serve regulated markets across North America, Europe and other geographies.
With integrated capabilities spanning development, scale-up and commercial manufacturing, Morepen aims to support complex, long-duration supply programs. The company said it is evaluating capacity expansion and technology investments to align with its expanding CDMO opportunity pipeline, signalling a calibrated approach toward scaling its global footprint.
Building Long-Term Manufacturing Partnerships
Commenting on the development, chairman and MD Sushil Suri described the mandate as a defining step in the evolution of the company’s manufacturing platform. “This mandate represents an important milestone in the evolution of Morepen’s manufacturing platform. It reflects the confidence global customers place in our quality systems, regulatory track record and execution capabilities. Over the years, we have steadily strengthened our infrastructure and compliance depth, enabling participation in larger, long-duration global programs,” Suri said.
He added that the CDMO business represents a natural extension of the company’s established API strengths, creating additional avenues for scale, revenue visibility and long-term value creation, while reinforcing its core pharmaceutical operations.
The order is expected to enhance earnings visibility over the execution period and further strengthen Morepen’s positioning as a reliable global manufacturing partner at a time when multinational pharmaceutical companies are increasingly diversifying their supply chains and seeking trusted, compliance-driven partners in India.